TORONTO, Jan. 25 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:
ARI), a biotechnology company discovering and developing the next wave of
antibody therapeutics, today announced it will hold a conference call to
discuss its fourth quarter and year end 2007 results at 8:00 a.m. (Eastern
Time) on Tuesday, January 29, 2008. The Company will report its results in
a press release to be issued at 7:00 a.m. prior to the call.
DATE: Tuesday, January 29, 2008
TIME: 8:00 a.m., Eastern Standard Time
WEBCAST: A live audio webcast of the call will be available at
http://www.ariusmabs.com. Webcast attendees are welcome to listen to the
conference in real-time or on-demand at their convenience. The webcast will
be archived for 365 days. Please connect to this website at least 15
minutes prior to the conference call to ensure adequate time for any
software download that may be needed to hear the webcast.
TAPED REPLAY: 416-644-3414 or 1-800-731-6941 (Available until
February 5, 2008)
REFERENCE NUMBER: 21261080
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved